Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)

Yao, 2008, One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States, J Clin Oncol, 26, 3063, 10.1200/JCO.2007.15.4377

Reubi, 1990, Distribution of somatostatin receptors in normal and tumor tissue, Metabolism, 39, 78, 10.1016/0026-0495(90)90217-Z

Srirajaskanthan, 2009, Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies, Neuroendocrinology, 89, 308, 10.1159/000179899

Davis, 1980, Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome, Gastroenterology, 78, 346, 10.1016/0016-5085(80)90586-7

Dharmsathaphorn, 1980, Somatostatin inhibits diarrhea in the carcinoid syndrome, Ann Intern Med, 92, 68, 10.7326/0003-4819-92-1-68

Long, 1981, Somatostatin, gastrointestinal peptides, and the carcinoid syndrome, Gut, 22, 549, 10.1136/gut.22.7.549

Pless, 2005, The history of somatostatin analogs, J Endocrinol Invest, 28, 1

Oberg, 2004, Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system, Ann Oncol, 15, 966, 10.1093/annonc/mdh216

Toumpanakis, 2009, Long-term results of patients with malignant carcinoid syndrome receiving Octreotide LAR, Aliment Pharmacol Ther, 30, 733, 10.1111/j.1365-2036.2009.04083.x

Ricci, 2000, Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide, Ann Oncol, 11, 1127, 10.1023/A:1008383132024

Rubin, 1999, Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome, J Clin Oncol, 17, 600, 10.1200/JCO.1999.17.2.600

Tomassetti, 2000, Treatment of gastroenteropancreatic neuroendocrine tumours with Octreotide LAR, Aliment Pharmacol Ther, 14, 557, 10.1046/j.1365-2036.2000.00738.x

Sassolas, 1989, Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men, J Clin Endocrinol Metab, 68, 239, 10.1210/jcem-68-2-239

Faiss, 2003, Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group, J Clin Oncol, 21, 2689, 10.1200/JCO.2003.12.142

Ruszniewski, 1996, Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients, Gut, 39, 279, 10.1136/gut.39.2.279

Caron, 2002, Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly, J Clin Endocrinol Metab, 87, 99, 10.1210/jc.87.1.99

Bajetta, 2006, Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study, Cancer, 107, 2474, 10.1002/cncr.22272

Ruszniewski, 2004, Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide, Neuroendocrinology, 80, 244, 10.1159/000082875

Rinke, 2009, Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group, J Clin Oncol, 27, 4656, 10.1200/JCO.2009.22.8510

Modlin, 2010, Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours, Aliment Pharmacol Ther, 31, 169, 10.1111/j.1365-2036.2009.04174.x

Plockinger, 2007, Neuroendocrine tumors. Biotherapy, Best Pract Res Clin Endocrinol Metab, 21, 145

Janson, 1993, Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon, Acta Oncol, 32, 225, 10.3109/02841869309083916

Raderer, 2001, Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid, Oncology, 60, 141, 10.1159/000055311

O’Toole, 2000, Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance, Cancer, 88, 770, 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0

Arnold, 1996, Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours, Gut, 38, 430, 10.1136/gut.38.3.430

Oberg, 1989, Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity, J Natl Cancer Inst, 81, 531, 10.1093/jnci/81.7.531

Di, 1996, Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group, Cancer, 77, 402, 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4

Modlin, 2003, A 5-decade analysis of 13,715 carcinoid tumors, Cancer, 97, 934, 10.1002/cncr.11105

Strosberg, 2009, Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors, Hum Pathol, 40, 1262, 10.1016/j.humpath.2009.01.010

Rindi, 2007, TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system, Virchows Arch, 451, 757, 10.1007/s00428-007-0452-1